Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Interest Expenses (2016 - 2023)

Cartesian Therapeutics (RNAC) has disclosed Interest Expenses for 9 consecutive years, with $1.3 million as the latest value for Q3 2023.

  • On a quarterly basis, Interest Expenses rose 58.73% to $1.3 million in Q3 2023 year-over-year; TTM through Jun 2024 was $1.3 million, a 59.83% decrease, with the full-year FY2023 number at $2.8 million, down 6.53% from a year prior.
  • Interest Expenses was $1.3 million for Q3 2023 at Cartesian Therapeutics, up from $752000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $1.3 million in Q3 2023 to a low of $205000.0 in Q2 2020.
  • A 5-year average of $620157.9 and a median of $711000.0 in 2021 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: surged 5683.33% in 2019, then crashed 48.75% in 2020.
  • Cartesian Therapeutics' Interest Expenses stood at $335000.0 in 2019, then soared by 112.84% to $713000.0 in 2020, then dropped by 0.28% to $711000.0 in 2021, then increased by 13.5% to $807000.0 in 2022, then skyrocketed by 57.74% to $1.3 million in 2023.
  • Per Business Quant, the three most recent readings for RNAC's Interest Expenses are $1.3 million (Q3 2023), $752000.0 (Q2 2023), and $808000.0 (Q1 2023).